FDA Clears ET-600 for Arginine Vasopressin Deficiency on February 25 PDUFA Date
On February 25, 2026, the FDA approved ET-600, an oral liquid formulation of desmopressin, for treating arginine vasopressin deficiency in pediatric patients. This marks a significant development as it is the first FDA-approved oral liquid therapy tailored for children with this rare disorder. The approval addresses longstanding challenges related to dosing precision and administration ease. The implications for safety and treatment outcomes in affected children warrant further examination.
ET-600, a proprietary oral solution formulation of desmopressin, has been developed by Eton Pharmaceuticals, Inc. (NASDAQ: ETON) specifically to treat central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D). This clearance marks a significant milestone in pediatric endocrinology, as ET-600 is targeted at approximately 3,000 pediatric patients in the United States who suffer from this rare condition.
Although treatment options for arginine vasopressin deficiency have been limited, the FDA has recently granted clearance for ET-600, a novel therapeutic agent designed to address this condition.
The FDA’s clearance of ET-600 follows the acceptance of the New Drug Application (NDA) and the Prescription Drug User Fee Act (PDUFA) target action date of February 25, 2026. This regulatory approval signifies that ET-600 meets the FDA’s stringent requirements for safety and efficacy in treating AVP-D in children. Importantly, ET-600 is designed to offer precise, titratable doses in an oral liquid form, addressing a critical unmet need in the management of this disorder. Prior to ET-600, treatment options were limited to off-label, compounded liquid suspensions or the cutting of fractional tablets, both of which presented challenges in dosing accuracy and safety.
The introduction of ET-600 offers a unique solution as the only oral liquid formulation approved for pediatric patients with AVP-D, improving dosing precision over current methods. This is particularly relevant for children, where accurate dosing is paramount to effective management and reduction of adverse effects. The oral liquid format of ET-600 is expected to enhance caregiver compliance and simplify administration, thereby improving overall treatment outcomes. Moreover, ET-600’s formulation and delivery method directly respond to the significant gap in available therapies for this patient population, which has long relied on suboptimal alternatives.
From a commercial perspective, Eton Pharmaceuticals is preparing for a potential launch of ET-600 in the first quarter of 2026, following FDA clearance. The company’s strategic move to secure patent protection for ET-600’s formulation until 2044, along with an additional patent application under review, positions ET-600 for long-term market exclusivity. This exclusivity is expected to support a high-value product opportunity, as no competing oral liquid options currently exist for AVP-D treatment. For more information, see shop on Amazon.
Financially, Eton Pharmaceuticals has demonstrated robust growth, with a market capitalization of $386 million and a 323% return over the past year. The company reported a 41% increase in revenue over the last twelve months, including a 117% year-over-year increase in Q1 2025 revenue to $17.3 million. Analysts anticipate continued sales growth driven by the launch of ET-600 and its capacity to fulfill a critical pediatric therapeutic need. The FDA’s clearance of ET-600 not only represents a breakthrough in treatment for arginine vasopressin deficiency but also signals a promising commercial future for Eton Pharmaceuticals in the rare disease space.
This article may contain affiliate links. If you make a purchase through these links, we may earn a small commission at no additional cost to you.
